Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
da VINci: OTSGC-A24 + Nivolumab +/- Ipilimumab in Gastric Cancer
NCT03784040Phase 1Unknown
- Sponsor
- National University Hospital
- Start
- Feb 2019
- Primary completion
- Mar 2023
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of OTSGC-A24 in gastric cancer (GC) (2 arms), sponsored by National University Hospital. Primary endpoints: Adverse Event and Adverse Drug Reaction at 3 years and Objective Response Rate at 3 years. Status: unknown.
02
Drugs
OTSGC-A24
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03784040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03784040.